These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Dendritic cell-based cancer immunotherapy]. Aruga A Nihon Rinsho; 2010 Jun; 68(6):1107-10. PubMed ID: 20535963 [TBL] [Abstract][Full Text] [Related]
9. The present status and future prospects of peptide-based cancer vaccines. Hirayama M; Nishimura Y Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694 [TBL] [Abstract][Full Text] [Related]
10. Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines. Dobrovolskienė N; Pašukonienė V; Darinskas A; Kraśko JA; Žilionytė K; Mlynska A; Gudlevičienė Ž; Mišeikytė-Kaubrienė E; Schijns V; Lubitz W; Kudela P; Strioga M Vaccine; 2018 Jul; 36(29):4171-4180. PubMed ID: 29895501 [TBL] [Abstract][Full Text] [Related]
11. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017 [TBL] [Abstract][Full Text] [Related]
13. Tumor cell lysates as immunogenic sources for cancer vaccine design. González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929 [TBL] [Abstract][Full Text] [Related]
14. Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. Herbert GS; Vreeland TJ; Clifton GT; Greene JM; Jackson DO; Hardin MO; Hale DF; Berry JS; Nichol P; Yin S; Yu X; Wagner TE; Peoples GE Vaccine; 2018 May; 36(23):3247-3253. PubMed ID: 29724512 [TBL] [Abstract][Full Text] [Related]
15. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
16. Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. Saxena M; Bhardwaj N Trends Cancer; 2018 Feb; 4(2):119-137. PubMed ID: 29458962 [TBL] [Abstract][Full Text] [Related]
18. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells. Ramachandran M; Dimberg A; Essand M Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957 [TBL] [Abstract][Full Text] [Related]
19. Review: cancer immunotherapy by exosome-based vaccines. Hao S; Moyana T; Xiang J Cancer Biother Radiopharm; 2007 Oct; 22(5):692-703. PubMed ID: 17979572 [TBL] [Abstract][Full Text] [Related]
20. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy. Rolinski J; Hus I J Immunotoxicol; 2014 Oct; 11(4):311-8. PubMed ID: 24495309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]